Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05133830 · ClinicalTrials.gov registry record · Phase 1
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT05133830 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 52 participants.
The verdict
NCT05133830, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of linerixibat and OCA.
Interventions
- DRUG Linerixibat
- DRUG Obeticholic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-11-23 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05133830
The ClinicalTrials.gov registry entry for NCT05133830 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Linerixibat is the first listed.
NCT05133830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05133830 about?
NCT05133830 is a clinical study titled "Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants". This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of linerixibat and OCA.
What is the current status of trial NCT05133830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2021-11-23. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT05133830?
The interventions under investigation include: Linerixibat (DRUG), Obeticholic acid (DRUG).
Who is sponsoring clinical trial NCT05133830?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.